uropean guidelines on cardiovascular disease prevention in clinical practice have identified obesity and smoking as primary risk factors for cardiovascular disease, the increased prevalence of which underlines the need for new therapeutic targets. The endocannabinoid (EC) system is a physiological system, comprising the cannabinoid receptors, cannabinoid type 1 (CB1) and type 2 (CB2), and their natural ligands, such as anandamide and 2-arachidonyl-glycerol (2-AG). The system plays a key role in energy balance regulation, both centrally and peripherally impacting on food intake, lipid and glucose metabolism, and fat accumulation. The EC system is also involved in nicotine dependence. Over activity of the EC system, associated with obesity or chronic tobacco use, leads to increased levels of endogenous ligands (endocannabinoids) and disrupts the feedback mechanism related to steady state homeostasis. Rimonabant, the first selective CB1 receptor blocker, normalises the EC system, reduces food intake and body weight, improves lipid and glucose metabolism and insulin sensitivity and reduces nicotine self-administration. Clinical trials are ongoing to support the therapeutic potential of rimonabant in reducing these multiple cardiovascular risk factors.
Peeters A., Barendregt JJ, Willekens F., Mackenbach JP, Al Mamun A., Bonneux L.; Nedcom.Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med2003;138(1):24-32.
2.
Yusuf S., Hawken S., Ôunpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet; http://image.thelancet.com/extras/04art8001web.pdf
3.
Han TS, Lean MEJMetabolic syndrome. Medicine1998;26:27-9.
4.
Bonora E., Targher G., Formentini G. et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med2004;21(1):52-8.
5.
Tsiara S., Elisaf M., Mikhailidis DPInfluence of smoking on predictors of vascular disease. Angiology2003;54:507-30.
6.
Department of Health.National Service Framework for Coronary Heart Disease: Modern standards and service models. HMSOLondon, 2000.
7.
Tuomilehto J. , Lindstrom J., Eriksson J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343-50.
8.
Knowler WC, Knowler WC, Barrett-Connor E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002 ;346:393-403.
9.
Torgerson JS , Hauptman J., Boldrin MN, Sjostrom L.XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care2004;27:155-61.
10.
Gaoni Y., Mechoulam R.Isolation, structure and partial synthesis of an active constituent of hashish . J Am Chem Soc1964;86:1646-7. 11. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett ACDetermination and characterization of a cannabinoid receptor in rat brain . Mol Pharmacol1988 ;34:605-13.
11.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TIStructure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature1990;346:561-4.
12.
Munro S., Thomas KL, Abu-Shaar M.Molecular characterization of a peripheral receptor for cannabinoids . Nature1993;365:61-5. 14. Howlett AC, Barth F., Bonner TI et al. International Union of Pharmacology. 27th. Classification of cannabinoid receptors. Pharmacol Reviews2002;54:161-202.
13.
Devane WA, Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science1992;258:1946-9. 16. Mechoulam R., Ben-Shabat S., Hanus L. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol1995;50(1):83-90.
14.
Sugiura T., Kondo S., Sukagawa A. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun1995;215(1):89-97.
15.
Hanus L., Abu-Lafi S., Fride E. et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA2001;98:3662-5.
16.
Porter AC, Sauer JM, Knierman MD et al. Characterization of a novel EC, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther2002;301:1020-4.
17.
Huang SM, Bisogno T., Trevisani M. et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA2002;99:8400-05.
18.
Di Marzo V., Fontana A., Cadas H. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature1994; 372:686-91.
19.
Di Marzo V., Melck D., Bisogno T., De Petrocellis L.Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosc1998;21:521-8.
20.
Di Marzo V., Bifulco M., De Petrocellis L.The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov2004;3:771-84.
21.
Cota D., Genghini S., Pasquali R., Pagotto U.Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity . J Endocrinol Invest2003;26: 1041-4.
22.
Qian S., Chen H., Weingarth D. et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol2002;22:5027-35.
23.
Cota D., Marsicano G., Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest2003;112:423-31.
24.
Di Marzo V. , Goparaju SK, Wang L. et al. Leptin-regulated ECs are involved in maintaining food intake. Nature2001;410:822-5.
25.
Ravinet Trillou C., Arnone M., Delgorge C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice . Am J Physiol Regul Integr Comp Physiol2003 ;284:R345-R353.
26.
Gomez R., Navarro M., Ferrer B. et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci2002; 22:9612-17.
27.
Cohen C., Perrault G., Voltz C., Steinberg R., Soubrié P.SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol2002; 13:451-63.
28.
Bensaid M., Gary-Bobo M., Esclangon A. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol2003;63:908-14.
29.
Gonzalez S. , Cascio MG, Fernandez-Ruiz J., Fezza F., Di Marzo V., Ramos JAChanges in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res2002;954:73-81.
30.
Rinaldi-Carmona M., Barth F., Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett1994; 350:240-4.
31.
Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrié P.CB1 cannabinoid-receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes2004 ;28:640-8.
32.
Yamauchi T. , Kamon J., Minokoshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med2002;8:1288-95.
33.
Yamauchi T. , Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med2001;7:941-6.
34.
Cohen C., Perrault G., Griebel G., Soubrie P.Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharm2004;30:145-55.
35.
Lange JH, Coolen HK, van Stuivenberg HH et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem2004;47:627-43.
36.
Reproduced with permission from ADIS RDInsight, 2005. Accessed 05.01.2005.
37.
Reproduced with permission from Pharmaprojects, 2005. Accessed 05.01.2005.
38.
www.acompliareport.com (accessed 05.01.2005).
39.
Van Gaal LF , Rissanen AM, Scheen AJ, Ziegler O., Rossner S.; RIO-Europe Study Group.Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet2005;365: 1389-97.
